08.28.26 -- Bench To Commercial: Scaling Biologics & Accelerating Development

We offer 20+ years of full-service biologics manufacturing, from drug substance development through Phase 1 and 2 clinical production, with FDA, EMA, and Health Canada-inspected facilities in Mississauga.

Optimizing host selection, media formulation, and analytical testing is critical to scaling protein production efficiently. Applying upstream strategies and high-throughput screening resolves bottlenecks, boosting overall yields while maintaining product quality.

Precision purification strategies can simplify microbial downstream processing. View how streamlined workflows help shorten development timelines while supporting protein production.

A science‑driven CRDO model accelerates biologic development by combining expert formulation, analytics, and partnerships to reduce risk and improve outcomes.

Streamline early biologics development by combining model-guided sequence selection with parallel scale-up strategies to overcome cell line unpredictability and reduce tech transfer risks.

High-speed fill-finish integrates automation, isolators, and scalable capacity to boost efficiency, protect product quality, and meet rising biologics demand from clinical through commercial. 

Advanced nanotechnology improves biologics with higher drug loads, better stability, new delivery routes, and enhanced performance in injectables, inhalation, and long‑acting therapies.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

To meet mAb, bispecific, and multispecific expression needs, sponsors require a proven cell line platform that delivers high‑titer, stable expression for complex proteins.

Learn about a manufacturing site with over 35 years of expertise in bioconjugation, APIs, excipients, and adjuvants manufacturing that helps clients accelerate drug development programs worldwide.

Surrozen was keen to get started on process development and manufacturing and needed a CDMO with experience developing and producing bispecific antibodies and fusion proteins.